DOI: 10.1007/s12017-016-8422-x Pages: 11-23
Article Type: Review Paper

Epigenetic Modifications and Therapy in Multiple Sclerosis

1. Tehran University of Medical Sciences, Department of Immunology, School of Medicine

2. University of Kentucky, Markey Cancer Center

3. Zabol University of Medical Sciences, Department of Immunology, Faculty of Medicine

4. Iran University of Medical Sciences, Department of Immunology, School of Medicine

5. Tabriz University of Medical Sciences, Immunology Research Center

6. Ardabil University of Medical Science, Department of Pharmacology, School of Medicine

Correspondence to:
Naser Jafari
Tel: (859) 230-9730
Email: naser.jafari@uky.edu

Close

Abstract

Breakthroughs in genetic studies, like whole human genome sequencing and genome-wide association studies (GWAS), have richened our knowledge of etiopathology of autoimmune diseases (AID) through discovery of genetic patterns. Nonetheless, the precise etiology of autoimmune diseases remains largely unknown. The lack of complete concordance of autoimmune disease in identical twins suggests that non-genetic factors also play a major role in determining disease susceptibility. Although there is no certain definition, epigenetics has been known as heritable alterations in gene function without changes in the nucleotide sequence. DNA methylation, histone modifications, and microRNA-associated gene expression suppression are the central mechanisms for epigenetic regulations. Multiple sclerosis (MS) is a disorder of the central nervous system (CNS), characterized by both inflammatory and neurodegenerative features. Although studies on epigenetic alterations in MS only began in the past decade, a mounting number of surveys suggest that epigenetic changes may be involved in the initiation and development of MS, probably through bridging the effects of environmental risk factors to genetics. Arming with clear understanding of epigenetic dysregulations underpins development of epigenetic therapies. Identifying agents inhibiting the enzymes controlling epigenetic modifications, particularly DNA methyltransferases and histone deacetylases, will be promising therapeutic tool toward MS. In the article underway, it is aimed to go through the recent progresses, attempting to disclose how epigenetics associates with the pathogenesis of MS and how can be used as therapeutic approach.

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Jun 30, 2016
  • Online: Jul 6, 2016

Article Tools